Abstract
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new infectious disease that first emerged in Hubei province, China, in December 2019. On 2 March 2020, the Moroccan Ministry of Health confirmed the first COVID-19 case in Morocco. The new virus SARS-CoV-2 was identified in the sample of a Moroccan expatriate residing in Italy. Without a therapeutic vaccine or specific antiviral drugs, early detection and isolation become essential against novel Coronavirus.
This study aims to analyze the epidemiological profile of the SARS-CoV-2 in Moroccan cases and to investigate the dynamic of RdRp, N, and E genes in patients from diagnosis until the recovery.
Among 859 COVID-19 RT-PCR tests realized for 376 patients, 187 cases had positive results COVID-19. 4% were positive with the 3 genes RdRp, N, and E, 40 % with N and E genes, 3% with RdRp and N genes, 31% with only the RdRp gene and 22% cases are positives with N gene. The analysis of the Covid-19 genes (RdRp, N, and E) dynamic reveal that more than 6% stay positive with detection of the N and E gene, and 14% with the N gene after 12 days of treatment.
The median period from positive to the first negative Covid-19 RT-PCR tests was 6.8±2.24 days for 44% cases, 14.31± 2.4 days for 30%, and 22.67 ± 1.21 days for 4%.
This a first description of the Moroccan COVID-19 cases and the analysis of the dynamic of the RdRp, N, and E genes. The analysis of our population can help to improve in the care of patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ethics committee of the Mohammed VI University of Health Sciences (UM6SS) of Morocco
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are not publicly available
